Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
Urinary hydroxyproline was elevated significantly in patients with untreated stage D prostatic carcinoma when compared to values in patients with benign prostatic hypertrophy and prostatic carcinoma without bony metastasis. Our results indicate that hydroxyproline may be a valuable marker in early staging, followup and evaluating treatment in prostatic cancer.